Clifford Capital Partners LLC purchased a new position in Solventum Co. (NYSE:SOLV – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 227,946 shares of the company’s stock, valued at approximately $12,054,000. Solventum comprises about 2.6% of Clifford Capital Partners LLC’s investment portfolio, making the stock its 26th biggest holding. Clifford Capital Partners LLC owned 0.13% of Solventum as of its most recent filing with the SEC.
Other hedge funds also recently bought and sold shares of the company. Davis Selected Advisers purchased a new stake in Solventum during the 2nd quarter valued at $273,070,000. Nuance Investments LLC purchased a new stake in shares of Solventum during the second quarter valued at $115,829,000. Newport Trust Company LLC purchased a new stake in shares of Solventum during the second quarter valued at $98,976,000. Baupost Group LLC MA bought a new stake in Solventum in the 2nd quarter worth about $96,242,000. Finally, Magnetar Financial LLC lifted its stake in Solventum by 2,880.8% during the 2nd quarter. Magnetar Financial LLC now owns 1,490,410 shares of the company’s stock valued at $78,813,000 after acquiring an additional 1,440,410 shares during the period.
Solventum Price Performance
NYSE:SOLV opened at $67.30 on Wednesday. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.31 and a quick ratio of 0.96. The firm’s 50-day moving average is $63.22. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $96.05.
Analyst Ratings Changes
SOLV has been the subject of several research reports. BTIG Research started coverage on shares of Solventum in a report on Thursday, September 5th. They set a “neutral” rating for the company. Wolfe Research initiated coverage on Solventum in a research note on Thursday, September 26th. They issued a “peer perform” rating on the stock. Wells Fargo & Company reduced their price objective on Solventum from $69.00 to $64.00 and set an “equal weight” rating for the company in a research report on Friday, August 9th. The Goldman Sachs Group raised their target price on Solventum from $48.00 to $54.00 and gave the stock a “sell” rating in a research report on Monday, August 12th. Finally, Morgan Stanley reduced their price target on shares of Solventum from $70.00 to $55.00 and set an “equal weight” rating for the company in a research report on Monday, July 15th. One investment analyst has rated the stock with a sell rating and seven have issued a hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $58.25.
Read Our Latest Stock Analysis on Solventum
About Solventum
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
See Also
- Five stocks we like better than Solventum
- The How and Why of Investing in Gold Stocks
- Analysts See 180% Upside for Rent the Runway: Should You Buy?
- Buy P&G Now, Before It Sets A New All-Time High
- Ready for Growth? Barrick Gold Stock Could Be the Answer
- When to Sell a Stock for Profit or Loss
- Trade Like a Member of Congress With These 2 ETFs
Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Co. (NYSE:SOLV – Free Report).
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.